BRIEF- GSK's Promacta/Revolade granted breakthrough therapy designation by FDA

Mon Feb 3, 2014 5:41am EST

Feb 3 (Reuters) - GlaxoSmithKline Plc : * GSK gains FDA breakthrough therapy designation for Promacta/Revolade (eltrombopag) for severe aplastic anaemia * Designation based on results from study in 43 heavily pretreated patients

with insufficient response to ist *

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.